Floatz logo

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC

Cancer Peritoneal

OncoMed Pharmaceuticals, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Cancer Peritoneal cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Irinotecan
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:

ovarian cancerDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →